DoseMeRx™, Achieves HITRUST CSF® Certification to Manage Risk, Improve Security Posture and Meet Compliance Requirements - Tabula Rasa HealthCare

DoseMeRx™, Achieves HITRUST CSF® Certification to Manage Risk, Improve Security Posture and Meet Compliance Requirements

Press Releases | Nov 03, 2020

Moorestown, NJ, November 3, 2020 – Tabula Rasa HealthCare, Inc. (TRHC) (NASDAQ: TRHC), a healthcare technology company advancing the field of medication safety, today announced its precision dosing platform DoseMeRx™ has earned Certified status for information security by HITRUST.

HITRUST CSF Certified status demonstrates that TRHC’s DoseMeRx platform has met key regulations and industry-defined requirements and is appropriately managing risk. By including federal and state regulations, standard frameworks, and incorporating a risk-based approach, the HITRUST CSF helps organizations address these challenges through a comprehensive and flexible framework of prescriptive and scalable security controls.

“DoseMeRx joins our other medication safety platforms already HITRUST CSF certified, including MedWise™, RxCompanion™, NiaRx-MedWise University Edition and EireneRx®,” said TRHC Chairman and CEO Calvin H. Knowlton, PhD. “DoseMeRx certification further demonstrates TRHC’s commitment to meeting the challenges of complex compliance requirements for our customers.”

“Obtaining HITRUST CSF certification, the widely adopted security and privacy framework for healthcare globally, reinforces our long-term commitment to improve the process of dosing complex drugs via safe, secure software solutions,” said Charles Cornish, TRHC Executive Vice President, Hospitals Business Unit.

“The comprehensive HITRUST CSF information protection framework has seen widespread adoption across industries while the HITRUST CSF Assurance Program brings a new level of effectiveness and efficiency to third-party assurance,” said Jeremy Huval, Chief Compliance Officer, HITRUST. “The HITRUST CSF Certification is now a common benchmark to measure organizations’ safeguards for sensitive data.”

Forward-Looking Statements
This press release includes forward-looking statements that we believe to be reasonable as of today’s date, including statements regarding Medication Risk Mitigation technology. Such statements are identified by use of the words “anticipates,” “believes,” “estimates,” “expects,” “intends,” “plans,” “predicts,” “projects,” “should,” and similar expressions. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: the need to innovate and provide useful products and services; risks related to changing healthcare and other applicable regulations; increasing consolidation in the healthcare industry; managing our growth effectively; our ability to adequately protect our intellectual property; and the other risk factors set forth from time to time in our filings with the SEC, including those factors discussed under the caption “Risk Factors” in our most recent annual report on Form 10-K, filed with the SEC on March 2, 2020, and in subsequent reports filed with or furnished to the SEC, copies of which are available free of charge within the Investor Relations section of the TRHC website ir.trhc.com or upon request from our Investor Relations Department. Any forward-looking statement speaks only as of the date on which it was made. TRHC assumes no obligation and does not intend to update these forward-looking statements, except as required by law, to reflect events or circumstances occurring after today’s date.

Share this:
Fill 1 Copy 2closeFill 5 Copy 4green-arrowhamburgerFill 7 Copy 4Fill 1 Copy 4pauseplaysearch-iconFill 3 Copy 4